- |||||||||| letaplimab (IBI188) / Innovent Biologics
Enrollment change, Trial completion date, Trial suspension, Trial primary completion date, Combination therapy: Safety and Efficacy of IBI188 With Azacitidine in Subjects With Newly Diagnosed Higher Risk MDS (clinicaltrials.gov) - Feb 16, 2023 P1, N=120, Suspended, N=126 --> 222 | Trial completion date: May 2022 --> Jun 2024 | Recruiting --> Suspended | Trial primary completion date: Apr 2021 --> Jun 2023 N=12 --> 120 | Trial completion date: Feb 2022 --> Aug 2024 | Recruiting --> Suspended | Trial primary completion date: Dec 2021 --> Dec 2023
- |||||||||| letaplimab (IBI188) / Innovent Biologics
Enrollment change, Trial completion date, Trial termination, Combination therapy, Metastases: IBI188 Combination Therapy in Solid Tumors (clinicaltrials.gov) - Oct 4, 2022 P1, N=9, Terminated, IBI188 in combination with azacitidine demonstrated promising efficacy, and a manageable safety profile as a first-line treatment in subjects with newly diagnosed higher risk myelodysplastic syndrome. N=120 --> 9 | Trial completion date: Oct 2022 --> Jul 2022 | Recruiting --> Terminated; No signs of efficacy in solid tumors
- |||||||||| azacitidine / Generic mfg.
Journal, IO biomarker: Combined strategies for effective cancer immunotherapy with a novel anti-CD47 monoclonal antibody. (Pubmed Central) - Feb 8, 2022 Notably, IBI188 treatment increased vascular endothelial growth factor-A (VEGF-A) levels in a solid tumor model, and combined treatment with an anti-VEGF-A antibody and IBI188 resulted in an enhanced anti-tumor effect. These data indicate that IBI188 is a therapeutic anti-CD47 antibody with anti-tumor potency, which can be enhanced when used in combination with standard-of-care drugs for cancer treatment.
- |||||||||| letaplimab (IBI188) / Innovent Biologics
Trial completion, Enrollment change, Trial completion date, Metastases: A Study Evaluating the Safety, Tolerability, and Initial Efficacy of Recombinant Human Anti-cluster Differentiation Antigen 47 (CD47) Monoclonal Antibody Injection (IBI188) in Patients With Advanced Malignant Tumors and Lymphomas (clinicaltrials.gov) - Dec 6, 2021 P1a, N=20, Completed, These data indicate that IBI188 is a therapeutic anti-CD47 antibody with anti-tumor potency, which can be enhanced when used in combination with standard-of-care drugs for cancer treatment. Active, not recruiting --> Completed | N=42 --> 20 | Trial completion date: Aug 2022 --> Mar 2021
- |||||||||| letaplimab (IBI188) / Innovent Biologics
Suppression of Extracellular Vesicle CD47 Induces Systemic Anti-DLBCL Immunity (GWCC - Hall A1) - Nov 5, 2021 - Abstract #ASH2021ASH_2207; P1b/2 Anti-CD47 antibody (IBI188) has shown promise in treating tumors, including Diffuse large B cell lymphoma (DLBCL)...Moreover, high levels of circulating EV CD47 would follow and correlate positively with the phagocytic activity of macrophages, and reflect the presence of a successful anti-tumor immunity elicited by the anti-CD47 therapy. Together, these findings show that EV CD47 represents an unexplored therapeutic target, which could overcome resistance to current CD47 antibody approaches.
- |||||||||| letaplimab (IBI188) / Innovent Biologics
Enrollment closed, Enrollment change, Trial primary completion date, Metastases: A Phase 1 Study Evaluating the Safety, Tolerability, and Initial Efficacy of IBI188 in Advanced Malignancies (clinicaltrials.gov) - Jul 21, 2021 P1, N=49, Active, not recruiting, Together, these findings show that EV CD47 represents an unexplored therapeutic target, which could overcome resistance to current CD47 antibody approaches. Recruiting --> Active, not recruiting | N=92 --> 49 | Trial primary completion date: Jul 2020 --> Nov 2021
- |||||||||| letaplimab (IBI188) / Innovent Biologics
Enrollment open, Combination therapy, Metastases: IBI188 Combination Therapy in Solid Tumors (clinicaltrials.gov) - Jul 20, 2021 P1, N=120, Recruiting, Recruiting --> Active, not recruiting | N=92 --> 49 | Trial primary completion date: Jul 2020 --> Nov 2021 Not yet recruiting --> Recruiting
|